• FirefoxUpgrade to the new Firefox »
  •  Dow Up0.15% Nasdaq Up0.36%

    Eventide Healthcare & Life Sciences N (ETNHX)

    21.12 Up 0.22(1.05%) Dec 19

    Profile as of Nov 29, 2014Get Profile for:
    Eventide Healthcare & Life Sciences N
    Mutual Fund Series Trust630-a Fitzwatertown Road 2nd Floor
    Phone: 877-771-3836
    Fund Overview 
    Fund Family:Eventide Funds
    Net Assets:130.04M
    Year-to-Date Return:17.60%
    Morningstar Rating:N/A
    Fund Inception Date:Dec 27, 2012
    Morningstar Style Box 
    [View Category Definition]
    View Top Health Funds
    About the Morningstar Style Box
    Management Information 
    Finny Kuruvilla
    Lead Manager since Dec 27, 2012
    Finny Kuruvilla holds an MD from Harvard Medical School, a PhD in Chemistry and Chemical Biology from Harvard University, a master’s degree in Electrical Engineering and Computer Science from MIT. Finny Kuruvilla has been a co-portfolio manager for the Eventide Gilead Fund since inception in July 2008 & manager of the Eventide Healthcare & Life Sciences Fund since inception in December 2012. Dr. Kuruvilla is also currently a Principal at Clarus Ventures, a healthcare and life sciences venture capital firm.
    Investment Information 
    Min Initial Investment:1,000
    Min Initial Investment, IRA:1,000
    Min Initial Investment, AIP:100
    Min Subsequent Investment:50
    Min Subsequent Investment, IRA:50
    Min Subsequent Investment, AIP:50
    ETNHX can be purchased from 24 brokerages.

    Fund Summary 
    The investment seeks to provide long-term capital appreciation. Under normal market conditions, the fund will invest at least 80% of its net assets (plus borrowings for investment purposes) in equity and equity-related securities of companies in the healthcare and life sciences sectors, including common stock, options, preferred stock and convertible debt. It is non-diversified.

    Fund Operations 
    Last Dividend : N/A
    Last Cap Gain : N/A
    Annual Holdings Turnover : 33.00%
    Average for Category:59.64%
    Fees & Expenses 
    ExpenseETNHXCategory Avg
    Annual Report Expense Ratio (net):1.63%1.43%
    Prospectus Net Expense Ratio:1.64%N/A
    Prospectus Gross Expense Ratio:1.70%N/A
    Max 12b1 Fee:0.20%N/A
    Max Front End Sales Load:N/A5.28%
    Max Deferred Sales Load: N/A2.37%
    3 Yr Expense Projection*:530612
    5 Yr Expense Projection*:917938
    10 Yr Expense Projection*:2,0041,843
    * Per $10,000 invested